A predictive scoring instrument for tuberculosis lost to follow-up outcome
- PMID: 22938040
- PMCID: PMC3490987
- DOI: 10.1186/1465-9921-13-75
A predictive scoring instrument for tuberculosis lost to follow-up outcome
Abstract
Background: Adherence to tuberculosis (TB) treatment is troublesome, due to long therapy duration, quick therapeutic response which allows the patient to disregard about the rest of their treatment and the lack of motivation on behalf of the patient for improved. The objective of this study was to develop and validate a scoring system to predict the probability of lost to follow-up outcome in TB patients as a way to identify patients suitable for directly observed treatments (DOT) and other interventions to improve adherence.
Methods: Two prospective cohorts, were used to develop and validate a logistic regression model. A scoring system was constructed, based on the coefficients of factors associated with a lost to follow-up outcome. The probability of lost to follow-up outcome associated with each score was calculated. Predictions in both cohorts were tested using receiver operating characteristic curves (ROC).
Results: The best model to predict lost to follow-up outcome included the following characteristics: immigration (1 point value), living alone (1 point) or in an institution (2 points), previous anti-TB treatment (2 points), poor patient understanding (2 points), intravenous drugs use (IDU) (4 points) or unknown IDU status (1 point). Scores of 0, 1, 2, 3, 4 and 5 points were associated with a lost to follow-up probability of 2,2% 5,4% 9,9%, 16,4%, 15%, and 28%, respectively. The ROC curve for the validation group demonstrated a good fit (AUC: 0,67 [95% CI; 0,65-0,70]).
Conclusion: This model has a good capacity to predict a lost to follow-up outcome. Its use could help TB Programs to determine which patients are good candidates for DOT and other strategies to improve TB treatment adherence.
Figures
References
-
- Frieden TR, Teklehaimanot A, Chideya S, Farmer P, Kim JY, Raviglione MC. A road map to control malaria, tuberculosis, and human immunodeficiency Virus/AIDS. Arch Intern Med. 2009;169(18):1650–1652. Available in: www.archinternmed.com. - PubMed
-
- Kochi A, Bumgarner R, Spinaci S, Kumaresan J, Raviglioni M, Hanson C. What is DOTS? A guide to understanding the WHO-recommended tuberculosis control strategy know as DOTs. Ginebra: World Health Organization; 1999.
-
- The Stop TB Strategy. Building on and enhancing DOTS to meetthe TB-related Millennium Development Goals. Genova: World Health Organization; 2006.
-
- Juan G, Lloret T, Pérez C, López P, Navarro R, Ramón M, Cortijo J, Morcillo EJ. Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. Int J Tuberc Lung Dis. 2006;10(2):215–221. - PubMed
-
- Snyder DC, Chin DP. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med. 1999;160:582–586. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
